Company Profile
Alzamend Neuro Stock Price, News & Analysis
- Ticker:
- ALZN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.34 USD (+0.75%)
Close
Last updated: July 27, 2026
4.34M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, ALZN closed up 0.75% at $1.34. No new same-company headline was identified in the current news window.
Company overview
Business overview
Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders. Its story is built around high-risk CNS development and novel treatment approaches.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Alzamend sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical validation, safety, and the ability to build a credible neuroscience franchise.
Position Within the Biotechnology Landscape
Alzamend is a highly catalyst-sensitive CNS name whose valuation is tied to early clinical progress.
Future catalysts
Alzamend’s catalysts are AL001 and any CNS-development step that keeps the platform alive. The company still needs stronger clinical proof.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
BCLI · Source: Brainstorm Cell Therapeutics Inc.
- 02
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
DNLI · Source: Denali Therapeutics
- 03
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
TNXP · Source: Tonix Pharmaceuticals
- 04
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
IKT · Source: Inhibikase Therapeutics
- 05
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
KTTA · Source: Pasithea Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Alzamend Neuro (ALZN)?
Alzamend Neuro (ALZN) most recently closed at 1.34 USD, a +0.75% move versus the previous session.
What is the market cap of Alzamend Neuro (ALZN)?
Alzamend Neuro currently has a market capitalization of 4.34M USD on BioPharmSignal.
What does Alzamend Neuro do?
Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders. Its story is built around high-risk CNS development and novel treatment approaches.
On which exchange is ALZN stock listed?
Alzamend Neuro (ALZN) is associated with NASDAQ, United States, Biopharma.
What is Alzamend?
Alzamend’s catalysts are AL001 and any CNS-development step that keeps the platform alive.
Which conditions is Alzamend Neuro targeting with Alzamend?
Alzamend Neuro is associated with neuroscience based on its company overview and current catalyst commentary.
How does Alzamend Neuro describe recent progress with Alzamend?
Alzamend’s catalysts are AL001 and any CNS-development step that keeps the platform alive.
What is Neuro?
Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders.